INTRODUCTION
The COVID-19 infection is now confirmed approximately 6 million
worldwide, and over 1.7 million in the United States (1). Acute
thrombotic events can occur during admission of COVID-19 (2). Among
patients with severe COVID-19 symptom admitted to ICU, high incidence of
venous thromboembolism has been reported despite prophylaxis (3).
Patients who developed acute respiratory distress syndrome (ARDS)
associated with COVID-19 showed significantly higher incidence of
pulmonary embolism compared to ARDS without COVID-19 (4). However, data
of hypercoagulability is still not available post-discharge after
recovering from COVID-19 ARVD (5).